Featured Research

from universities, journals, and other organizations

Donating kidney does not appear to significantly increase long-term risk of death

Date:
March 15, 2010
Source:
JAMA and Archives Journals
Summary:
An analysis of outcomes for live kidney donors in the US over a 15 year period finds they have similar long-term survival rates compared to healthy individuals who were not kidney donors, according to a new study.

An analysis of outcomes for live kidney donors in the U.S. over a 15 year period finds they have similar long-term survival rates compared to healthy individuals who were not kidney donors, according to a study in the March 10 issue of JAMA.

Many patients with end-stage renal (kidney) disease are turning to live donor kidney transplantation to improve survival and quality of life because of the shortage of organs available from the deceased donor pool. "Although many healthy adults are eager and willing to accept the risk of donor nephrectomy [surgical removal of a kidney] to help their loved ones, the responsibility lies within the medical community to quantify these risks as best as possible and to make this information available to those considering donation," the authors write. More than 6,000 healthy U.S. individuals every year undergo nephrectomy for the purposes of live donation; however, safety remains in question because of the limited generalizability of previous studies, according to background information in the article.

Dorry L. Segev, M.D., Ph.D., of the Johns Hopkins University School of Medicine, Baltimore, and colleagues examined the outcomes of live kidney donors (80,347) in the United States between April 1, 1994, and March 31, 2009, who were drawn from a mandated national registry. Median (midpoint) follow-up was 6.3 years. A matched group was drawn from 9,364 participants of the third National Health and Nutrition Examination Survey (NHANES III).

During the study period, there were 25 deaths within 90 days of live kidney donation, with the risk of death being 3.1 per 10,000 donors, compared to a rate of death for the NHANES III matched group of 0.4 per 10,000 persons. By 1 year following nephrectomy, risk of death in the matched group was similar to the live donor group, likely representing deaths attributable to comorbidity (co-existing illnesses) rather than death because of the surgery. The researchers found that long-term mortality was similar or lower for live kidney donors than for the matched NHANES III group throughout the 12-year period of follow-up (5-year follow-up, 0.4 percent vs. 0.9 percent; 12-year follow-up, 1.5 percent vs. 2.9 percent, respectively).

"Surgical mortality did not change during the 15-year period, despite differences in surgical practice and donor selection. Men had a statistically significantly higher surgical mortality than women did, as did black individuals vs. white and Hispanic individuals," the authors write. Donors with hypertension also had a statistically significantly higher surgical mortality than did donors without hypertension.

"Regardless of what physiologic changes might occur in a healthy adult after kidney donation, our findings of similar long-term survival between donors and healthy comparison patients suggest that these physiologic changes do not result in premature death. Although additional studies are clearly needed to better understand the physiologic changes after kidney donation, the current practice of live kidney donation should continue to be considered a reasonable and safe modality for addressing the profound shortage in deceased donor organs," the authors conclude.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dorry L. Segev; Abimereki D. Muzaale; Brian S. Caffo; Shruti H. Mehta; Andrew L. Singer; Sarah E. Taranto; Maureen A. McBride; Robert A. Montgomery. Perioperative Mortality and Long-term Survival Following Live Kidney Donation. JAMA, 2010; 303 (10): 959-966 [link]

Cite This Page:

JAMA and Archives Journals. "Donating kidney does not appear to significantly increase long-term risk of death." ScienceDaily. ScienceDaily, 15 March 2010. <www.sciencedaily.com/releases/2010/03/100309161830.htm>.
JAMA and Archives Journals. (2010, March 15). Donating kidney does not appear to significantly increase long-term risk of death. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/03/100309161830.htm
JAMA and Archives Journals. "Donating kidney does not appear to significantly increase long-term risk of death." ScienceDaily. www.sciencedaily.com/releases/2010/03/100309161830.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins